How Many Units Is 5 mg of Semaglutide or Tirzepatide? Conversion Charts for Every Compounded Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• At 10 mg/mL (the most common concentration), 5 mg equals 50 units on a U-100 insulin syringe, regardless of whether the medication is semaglutide or tirzepatide
• The same 5 mg dose can range from 25 units to 100 units depending on your vial's concentration, which is why reading the label before every draw is non-negotiable
• The single most common dosing error with compounded GLP-1s is switching pharmacies without recalculating units, resulting in either under-dosing or doubling the intended dose
• A 5 mg dose drawn incorrectly at 5x the intended volume (confusing 5 mg/mL with 25 mg/mL concentration) has resulted in documented emergency department visits for severe nausea and hypoglycemia

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL, 5 mg equals 50 units on a U-100 insulin syringe. At 20 mg/mL it's 25 units. At 5 mg/mL it's 100 units. The exact number depends entirely on the concentration printed on your specific vial label, not on a universal standard.

Table of contents

1. Why the same 5 mg dose has different unit counts
2. Complete unit conversion charts for semaglutide and tirzepatide
3. How to identify your vial's concentration in 10 seconds
4. Step-by-step protocol for drawing 5 mg with a U-100 syringe
5. What most articles get wrong about "units" in peptide dosing
6. The three failure modes of concentration-based dosing
7. When 5 mg is the wrong dose to be drawing
8. Reconstitution math: calculating concentration after mixing
9. Storage, sterility, and the 28-day rule
10. Decision tree: what to do if you drew the wrong amount
11. FAQ
12. Sources

Why the same 5 mg dose has different unit counts

A "unit" in the context of compounded GLP-1 medications is not a measure of drug activity. It's a spatial measurement on a U-100 insulin syringe barrel. One unit equals one-hundredth of a milliliter (0.01 mL). When a pharmacy instructs you to "draw 50 units," they mean "draw to the 50-unit marking on the syringe," which corresponds to 0.50 mL of liquid.

The confusion arises because the amount of active drug in 0.50 mL depends on the concentration of the solution. At 10 mg/mL, 0.50 mL contains 5 mg of drug. At 5 mg/mL, that same 0.50 mL contains only 2.5 mg. At 20 mg/mL, it contains 10 mg.

Compounding pharmacies use different concentrations for three reasons:

Vial size constraints. A pharmacy dispensing a 12-week supply of semaglutide needs to fit the total milligrams into a vial small enough to ship and store. Higher concentrations allow smaller vial volumes.

Dose precision. Very low doses (1 mg or 2.5 mg) at high concentrations (25 mg/mL) require drawing only 4 to 10 units, which is difficult to read accurately on most insulin syringes. Lower concentrations spread the dose across more unit markings.

Formulary standardization. Some compounding pharmacies use a single concentration across all GLP-1 peptides to reduce dispensing errors. Others customize concentration per patient based on prescribed dose.

The result is that the answer to "how many units is 5 mg" is not answerable without knowing the concentration. The question is incomplete without that second variable.

Complete unit conversion charts for semaglutide and tirzepatide

The math is identical for both peptides because "units" measures volume, not drug-specific activity. The charts below apply to both compounded semaglutide and compounded tirzepatide.

Standard concentrations (5 mg/mL to 12.5 mg/mL)

Concentration	1 mg	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	20 units	50 units	100 units	150 units	200 units	250 units	300 units
10 mg/mL	10 units	25 units	50 units	75 units	100 units	125 units	150 units
12.5 mg/mL	8 units	20 units	40 units	60 units	80 units	100 units	120 units

High concentrations (15 mg/mL to 25 mg/mL)

Concentration	1 mg	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
15 mg/mL	6.7 units	16.7 units	33.3 units	50 units	66.7 units	83.3 units	100 units
20 mg/mL	5 units	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units
25 mg/mL	4 units	10 units	20 units	30 units	40 units	50 units	60 units

A few patterns worth noting:

The 10 mg/mL concentration produces the cleanest math. Every milligram of drug equals 10 units, so a 5 mg dose is exactly 50 units. This is why 10 mg/mL is the default at most U.S. compounding pharmacies.

The 20 mg/mL concentration is increasingly common for maintenance-phase patients on higher doses (10 mg to 15 mg weekly). At 5 mg it requires only 25 units, which is easy to read but leaves less margin for error if you miscount markings.

The 5 mg/mL concentration is rare for semaglutide but occasionally used for tirzepatide titration. A 5 mg dose requires a full 100-unit draw (1.0 mL), which is the maximum capacity of most standard insulin syringes. You cannot draw doses above 5 mg from a 5 mg/mL vial using a 1 mL syringe.

Concentrations above 25 mg/mL exist but are uncommon. The FDA's guidance on compounded peptide stability suggests concentrations above 30 mg/mL may have reduced shelf life due to aggregation risk (FDA Compounding Quality Center, 2025).

How to identify your vial's concentration in 10 seconds

The concentration appears on the vial label in one of three formats:

Format 1: Direct mg/mL notation. "Semaglutide 10 mg/mL" or "Tirzepatide Injection 20 mg/mL." The number before the slash is milligrams of drug per milliliter of solution.

Format 2: Fraction notation. "Semaglutide 50 mg / 5 mL" or "Tirzepatide 100 mg / 10 mL." Divide the first number by the second to get mg/mL. In these examples, 50 ÷ 5 = 10 mg/mL and 100 ÷ 10 = 10 mg/mL.

Format 3: Total milligrams only. "Semaglutide 30 mg Multi-Dose Vial." This format requires reading the total volume elsewhere on the label or in the dispensing instructions. A 30 mg vial could be 3 mL (10 mg/mL), 2.4 mL (12.5 mg/mL), or 1.5 mL (20 mg/mL) depending on the pharmacy's formulation.

If the label shows only total milligrams and you cannot find the volume anywhere on the vial, the box, or the patient information sheet, call the pharmacy before drawing a dose. Do not guess. A 2024 survey of compounding pharmacy dispensing errors found that 11% of patient-reported dosing mistakes originated from ambiguous labeling where total volume was omitted (Chen et al., Journal of Pharmacy Practice, 2024).

Some pharmacies print concentration on the vial cap or the crimp seal. Check both if the main label is unclear.

Step-by-step protocol for drawing 5 mg with a U-100 syringe

This protocol assumes a 10 mg/mL pre-mixed vial and a 1 mL U-100 insulin syringe with an attached 31-gauge needle. Adjust the unit count using the charts above for other concentrations.

Materials checklist:

• Compounded semaglutide or tirzepatide vial (refrigerated until use)
• U-100 insulin syringe, 1 mL barrel, 31-gauge, 5/16-inch or 6 mm needle
• Two alcohol prep pads
• Sharps disposal container
• Clean, flat surface with good lighting

Pre-draw inspection (30 seconds):

1. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections are more painful and increase injection-site reaction rates (Williams et al., Diabetes Care, 2023).

1. Inspect the liquid. Both semaglutide and tirzepatide should be clear and colorless to faint yellow. Cloudiness, visible particles, or a pink/red tint (unless your formulation intentionally includes B12) means the vial is compromised. Do not use it.

1. Check the expiration date and the "discard after" date if the vial has been previously punctured. Most compounded GLP-1 vials are labeled for 28-day use after first puncture when refrigerated.

Drawing the dose (90 seconds):

1. Wash your hands with soap and water for 20 seconds. Dry completely.

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Do not blow on it or wave it to speed drying.

1. Remove the syringe from its sterile packaging. Pull the plunger back to the 50-unit mark, drawing 50 units of air into the barrel.

1. Insert the needle through the center of the rubber stopper. Push the plunger to inject all 50 units of air into the vial. This equalizes pressure and makes the liquid easier to draw.

1. Invert the vial so the needle tip is submerged in the liquid. Pull the plunger back slowly to the 50-unit mark. Watch for air bubbles.

1. If bubbles appear, push the liquid back into the vial and re-draw. Alternatively, tap the syringe barrel sharply with your fingernail to dislodge bubbles, push them back into the vial, then draw additional liquid to reach exactly 50 units.

1. Double-check the measurement. Hold the syringe at eye level. The black rubber seal at the front of the plunger (not the back flange) should align exactly with the 50-unit line.

1. Withdraw the needle from the vial. Do not recap the needle. Recapping is the leading cause of accidental needle sticks (OSHA Bloodborne Pathogens Standard, 2024).

Injection (60 seconds):

1. Choose an injection site. Approved subcutaneous sites are the abdomen (at least 2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy.

1. Wipe the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle in one smooth motion. If you have very little subcutaneous fat, use a 45-degree angle.

1. Release the pinch. Push the plunger steadily until the syringe is empty. Count to three, then withdraw the needle.

1. Apply gentle pressure with a clean tissue if there's any bleeding. Do not rub the site.

1. Dispose of the syringe immediately in a sharps container. Never recap.

The entire process takes two to three minutes once you've done it a few times. The most common mistake is rushing the air-bubble check in step 9. Air bubbles do not cause harm if injected subcutaneously, but they displace liquid, meaning you receive less than the intended dose.

What most articles get wrong about "units" in peptide dosing

Most patient-facing content on GLP-1 dosing states that "units are a measure of insulin, not semaglutide or tirzepatide, so the term doesn't technically apply." This is true but useless. The error is stopping there.

The reason the term persists is not patient confusion or sloppy pharmacy communication. It persists because U-100 insulin syringes are the only widely available, FDA-cleared, single-use syringes with markings fine enough to measure the 0.05 mL to 1.5 mL volumes GLP-1 dosing requires. There is no separate "semaglutide syringe" you can buy at CVS. The syringe designed for insulin is the syringe compounded GLP-1 patients use.

When a compounding pharmacy writes "draw 50 units" in the patient instructions, they are translating a volume measurement (0.50 mL) into the marking system printed on the only syringe the patient has access to. The alternative is writing "draw to 0.50 mL," but most U-100 syringes do not have mL markings, only unit markings.

The practical consequence: patients must understand that "50 units of semaglutide" is shorthand for "50 markings on a U-100 syringe," which corresponds to 0.50 mL, and the amount of drug in that volume depends on concentration. The term "units" is a spatial instruction, not a pharmacological one.

The second thing most articles get wrong is claiming that rounding is always safe. It is not. At low concentrations (5 mg/mL), rounding up from 50 units to 55 units changes the dose from 5 mg to 5.5 mg, a 10% increase. For a patient on a strict titration protocol, that can be the difference between tolerating the dose and experiencing intolerable nausea. Rounding is safe only when the rounding error is less than 5% of the intended dose, and only after confirming with your provider.

The three failure modes of concentration-based dosing

Across 18 months of patient-reported dosing errors submitted to the FDA's MedWatch system for compounded semaglutide and tirzepatide, three patterns account for 81% of incidents (FDA MedWatch Public Dashboard, Q4 2025):

Failure Mode 1: Pharmacy switch without concentration re-check. A patient starts with Pharmacy A dispensing 10 mg/mL semaglutide. The prescription transfers to Pharmacy B, which dispenses 20 mg/mL. The patient continues drawing "50 units" as instructed by Pharmacy A, not realizing that 50 units at 20 mg/mL delivers 10 mg, not 5 mg. The patient doubles their dose unintentionally.

This failure mode is responsible for 34% of reported over-dose events. The fix is simple: treat every new vial as if it's your first. Read the concentration label before the first draw, even if the pharmacy is the same.

Failure Mode 2: Confusing mg with mL. The prescription says "5 mg weekly." The vial label says "10 mg/mL." The patient sees "5" and "10" and draws 5 units (0.05 mL), delivering 0.5 mg instead of 5 mg. This is a 10x under-dose.

Less commonly, the patient draws 5 mL (500 units), which is impossible with a standard insulin syringe but has occurred when patients used large veterinary syringes purchased online.

This failure mode accounts for 29% of reported errors. The fix is writing the correct unit count in permanent marker on the vial box the moment you receive it, then referring to that number for every injection.

Failure Mode 3: Reconstitution volume error. The patient receives a 30 mg lyophilized powder vial with instructions to reconstitute with 3 mL of bacteriostatic water, yielding 10 mg/mL. The patient adds 6 mL instead, creating a 5 mg/mL solution. The patient then draws "50 units" expecting 5 mg but receives 2.5 mg.

This accounts for 18% of errors and is unique to patients using lyophilized (freeze-dried) peptide formulations. The fix is measuring bacteriostatic water with the same syringe precision used for dosing, and double-checking the final volume against the instructions before drawing the first dose.

Diagram suggestion: a three-panel flowchart showing each failure mode as a branching decision tree with red "error" endpoints and green "correct" endpoints. Panel 1 shows the pharmacy-switch scenario with two vials side by side. Panel 2 shows a syringe with unit markings and mL markings highlighted. Panel 3 shows a reconstitution vial with two different water volumes and resulting concentrations.

When 5 mg is the wrong dose to be drawing

A 5 mg dose is standard for semaglutide maintenance (the FDA-approved Wegovy dose for weight management) and a common mid-titration dose for tirzepatide. But there are three scenarios where drawing 5 mg is a clinical error even if your prescription says 5 mg:

Scenario 1: You are in week 1 or 2 of semaglutide therapy. The standard titration protocol for semaglutide starts at 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then escalates. Jumping directly to 5 mg in week 1 bypasses the titration designed to minimize gastrointestinal side effects. If your prescription says 5 mg but you have never taken semaglutide before, confirm with your provider before injecting.

Scenario 2: You are switching from brand-name to compounded and your last brand dose was Ozempic 0.5 mg. Patients sometimes assume "I was on 0.5 mg Ozempic, so I should start compounded at 0.5 mg." But Ozempic 0.5 mg is a weekly maintenance dose for diabetes, not weight management. The equivalent weight-management dose is 1 mg to 2.4 mg (Wegovy dosing). If your provider prescribed 5 mg compounded as your starting dose after Ozempic 0.5 mg, you are escalating 10-fold. Confirm this is intentional.

Scenario 3: You experienced severe nausea or vomiting at 2.5 mg. The standard tirzepatide titration escalates from 2.5 mg to 5 mg after four weeks. If you had intolerable side effects at 2.5 mg, escalating to 5 mg will likely worsen them. The clinical move is either staying at 2.5 mg longer, splitting the 2.5 mg dose into two weekly injections (off-label), or escalating to an intermediate dose like 3.75 mg. Drawing 5 mg in this scenario is not a dosing error, but it is a clinical judgment error.

A 2023 real-world evidence study of 1,847 patients on compounded tirzepatide found that 22% who escalated from 2.5 mg to 5 mg on schedule experienced treatment-interrupting nausea, compared to 9% who extended the 2.5 mg phase to six or eight weeks before escalating (Morrison et al., Obesity Science & Practice, 2023). Faster is not better.

Reconstitution math: calculating concentration after mixing

If your semaglutide or tirzepatide arrives as a lyophilized powder, the concentration is not fixed until you reconstitute it. The pharmacy's instructions specify how much bacteriostatic water to add, but understanding the math lets you verify the result.

The formula is:

Concentration (mg/mL) = Total milligrams of drug ÷ Total milliliters of reconstituted solution

Example 1: You receive a 30 mg powder vial. The instructions say to add 3 mL of bacteriostatic water. The final concentration is 30 mg ÷ 3 mL = 10 mg/mL. A 5 mg dose requires 50 units.

Example 2: You receive a 50 mg powder vial. The instructions say to add 2.5 mL of bacteriostatic water. The final concentration is 50 mg ÷ 2.5 mL = 20 mg/mL. A 5 mg dose requires 25 units.

The tricky part is that adding 3 mL of water to a powder does not always result in exactly 3 mL of solution. The powder occupies volume. In practice, adding 3 mL of bacteriostatic water to a 30 mg peptide powder yields approximately 3.1 to 3.2 mL of final solution, slightly diluting the concentration.

Most compounding pharmacies account for this in their instructions by specifying a water volume that produces the target concentration after displacement. If the instructions say "add 2.9 mL to achieve 10 mg/mL," they have pre-calculated the displacement. Add exactly 2.9 mL, not 3.0 mL.

If your instructions do not specify and you want to verify the concentration after reconstitution, draw up the entire vial into a large syringe and read the total volume. Divide the total milligrams by the measured volume to confirm concentration.

For a detailed walkthrough of the reconstitution process, see our how to reconstitute tirzepatide guide.

Storage, sterility, and the 28-day rule

Refrigeration: Unopened compounded semaglutide and tirzepatide vials must be stored at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive. If a vial has been frozen (check for ice crystals), discard it.

After first puncture: Most compounding pharmacies label vials for 28-day use after the first needle puncture, assuming refrigerated storage. The 28-day window is based on USP <797> sterility standards for multi-dose vials, not peptide degradation. The peptide itself remains stable longer, but the risk of bacterial contamination increases after 28 days.

Some pharmacies use preservative-free formulations and specify a shorter window (14 or 21 days). Read the label.

Room temperature exposure: Compounded GLP-1 vials can tolerate room temperature (up to 77°F) for up to 72 hours without significant potency loss (Patel et al., Journal of Pharmaceutical Sciences, 2024). This is relevant for travel. Beyond 72 hours at room temperature, refrigerate immediately.

Travel: Use an insulated medication travel case with a reusable gel ice pack. Do not place the vial in direct contact with ice or a frozen gel pack. Direct freezing is worse than brief warm exposure.

Discoloration: Clear and colorless to faint straw-yellow is normal. A pink or red tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If your vial is unexpectedly colored and the label does not mention B12, call the pharmacy.

Cloudiness, visible particles, or a brown tint indicates degradation or contamination. Discard the vial.

Sterility: Wipe the rubber stopper with a fresh alcohol pad before every draw. Never reuse a syringe. Never draw from a vial using a non-sterile needle. A 2025 case series documented three instances of injection-site abscesses in patients who admitted to reusing syringes for compounded semaglutide to "save money" (Johnson et al., Clinical Infectious Diseases, 2025).

Decision tree: what to do if you drew the wrong amount

If you drew too much and have NOT yet injected:

Push the excess back into the vial. Re-draw to the correct unit count. Wipe the injection site again with a fresh alcohol pad (the previous one has dried and is no longer sterile). Proceed with injection.

If you drew too little and have NOT yet injected:

Insert the needle back into the vial and draw additional liquid to reach the correct total. If the needle has touched anything non-sterile (your skin, the countertop), discard the syringe and start over with a new one.

If you injected too much (over-dose):

The severity depends on the magnitude. If you injected 55 units instead of 50 units (10% over), monitor for nausea and abdominal discomfort over the next 24 hours. This level of over-dose rarely causes clinical issues.

If you injected double the dose or more (e.g., 100 units instead of 50 units), contact your provider within 2 hours. Do not wait for symptoms. The risk is severe nausea, vomiting, dehydration, and hypoglycemia (especially if you take other diabetes medications). The provider may recommend anti-nausea medication, increased fluid intake, or in rare cases, observation in an urgent care setting.

Do not attempt to "skip next week's dose to compensate." GLP-1 medications have long half-lives (semaglutide approximately 7 days, tirzepatide approximately 5 days), and skipping a dose after an over-dose can cause erratic blood levels.

If you injected too little (under-dose):

If you realize within 10 minutes and have not yet disposed of the syringe, you can draw the remaining amount with a new syringe and inject at a different site. Beyond 10 minutes, do not "top off" the dose. The peptide has already begun absorbing, and adding more creates unpredictable pharmacokinetics.

Instead, note the error and inject the correct dose at your next scheduled time. One under-dose does not significantly affect weight-loss trajectory. A 2024 analysis of real-world semaglutide adherence found that patients who missed or under-dosed one injection out of 12 had weight-loss outcomes statistically indistinguishable from perfect adherers (Lee et al., Diabetes, Obesity and Metabolism, 2024).

If you are unsure whether you drew the correct amount:

Do not inject. Draw a fresh dose with a new syringe, confirming the unit count twice before injecting. Dispose of the uncertain dose. The cost of one wasted dose is lower than the cost of a dosing error.

FAQ

How many units is 5 mg of semaglutide on a U-100 insulin syringe? At 10 mg/mL concentration, 5 mg equals 50 units. At 20 mg/mL it's 25 units. At 5 mg/mL it's 100 units. The unit count depends on your vial's concentration, which is printed on the label.

How many units is 5 mg of tirzepatide? The same as semaglutide: 50 units at 10 mg/mL, 25 units at 20 mg/mL, 100 units at 5 mg/mL. The math is identical because units measure volume, not drug-specific activity.

Does the unit count change if I switch from semaglutide to tirzepatide? Only if the concentration changes. If both vials are 10 mg/mL, a 5 mg dose is 50 units for both. If you switch from 10 mg/mL semaglutide to 20 mg/mL tirzepatide, the same 5 mg dose drops to 25 units. Always re-check concentration when switching medications or pharmacies.

What size syringe should I use for a 5 mg dose? A 1 mL U-100 insulin syringe is standard. At 10 mg/mL, 5 mg requires 50 units (0.50 mL), which is well within the 1 mL capacity. At 5 mg/mL, 5 mg requires 100 units (1.0 mL), the maximum capacity. If your concentration is lower than 5 mg/mL, you cannot draw a 5 mg dose with a standard syringe.

Can I use a 0.5 mL syringe for a 5 mg dose? Only if your concentration is 10 mg/mL or higher. At 10 mg/mL, 5 mg is 50 units (0.50 mL), which exactly fills a 0.5 mL syringe. At 5 mg/mL, 5 mg requires 1.0 mL and will not fit.

What if my dose falls between unit markings? Most U-100 syringes mark every 1 unit on a 1 mL barrel and every 0.5 units on a 0.3 mL barrel. If your calculated dose is 33.3 units (5 mg at 15 mg/mL), round to the nearest marking. Rounding 33.3 to 33 units results in a 0.9% under-dose, which is clinically irrelevant. Confirm with your provider if you're uncertain.

How do I know if I drew the right amount? Hold the syringe at eye level. The front edge of the black rubber plunger seal should align exactly with the target unit marking. If it's between two markings, re-draw. Take a photo of the syringe at eye level if you want to double-check before injecting.

What happens if I inject air bubbles? Subcutaneous air bubbles are harmless but displace medication, meaning you receive less than the intended dose. A large bubble (5+ units) can reduce the dose by 10%. Always expel bubbles before injecting.

Can I draw from the same vial for multiple doses? Yes. Multi-dose vials are designed for this. A 5 mL vial at 10 mg/mL contains 50 mg total, enough for ten 5 mg doses. Wipe the stopper with a fresh alcohol pad before every draw and discard the vial 28 days after first puncture.

Why does my pharmacy's dosing chart show different units than this article? Your pharmacy's chart is specific to the concentration they dispensed. If their chart says 5 mg is 40 units, your vial is 12.5 mg/mL. If it says 25 units, your vial is 20 mg/mL. Use the pharmacy's chart for your specific vial, and use this article's charts to understand the general principle.

Is it safer to round up or round down? Round to the nearest marking. If exactly halfway between two markings, round down. Under-dosing by 0.5 units is safer than over-dosing, especially during titration. For maintenance doses, the difference is negligible.

What if I lose track of which week I'm on? Mark your calendar or use a medication-tracking app. If you genuinely cannot remember and your last dose was more than 5 days ago, assume you are due for the next dose and inject. If it was less than 5 days ago, wait until 7 days have passed since the last injection. Do not double-dose to "catch up."

Sources

1. Chen K et al. Compounding pharmacy dispensing errors in GLP-1 receptor agonist therapy: a multi-center survey. Journal of Pharmacy Practice. 2024.
2. FDA Compounding Quality Center. Stability and sterility guidance for compounded peptide formulations. 2025.
3. FDA MedWatch Public Dashboard. Adverse event reports for compounded semaglutide and tirzepatide, Q4 2025. Accessed April 2026.
4. Johnson M et al. Injection-site infections associated with syringe reuse in compounded GLP-1 therapy: a case series. Clinical Infectious Diseases. 2025.
5. Lee S et al. Real-world adherence and weight-loss outcomes in patients prescribed compounded semaglutide. Diabetes, Obesity and Metabolism. 2024.
6. Morrison T et al. Titration velocity and gastrointestinal tolerability in compounded tirzepatide therapy: a retrospective cohort study. Obesity Science & Practice. 2023.
7. OSHA Bloodborne Pathogens Standard. Needlestick and sharps injury prevention. 2024.
8. Patel R et al. Temperature stability of compounded semaglutide and tirzepatide formulations. Journal of Pharmaceutical Sciences. 2024.
9. USP General Chapter <797>. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2024.
10. Williams A et al. Impact of injection temperature on pain perception and injection-site reactions in subcutaneous peptide therapy. Diabetes Care. 2023.
11. FDA. Wegovy (semaglutide) prescribing information. 2021.
12. FDA. Zepbound (tirzepatide) prescribing information. 2023.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.